Schein sees slight increase in first-quarter results; Gour inks research partnership for dermatitis drug; Orion scores double-digit profit growth;

> Distributor Henry Schein ($HSIC) announced that net sales in the first quarter rose 1% year over year to $2.5 billion and that net income excluding restructuring costs was up 6% to $108.4 million. Release

> Gour Medical announced that it has formed its first research partnership with the French National Center for Scientific Research, which will be centered around developing a recombinant monoclonal antibody to treat atopic dermatitis in dogs. Release

> Orion Group reported that its first-quarter revenues rose 6% year over year to $259.9 million and its profit before taxes jumped 24% to $82.7 million. Release (PDF)

> VetStem Biopharma, which is developing regenerative therapies for the animal health market, announced its has appointed Jeffrey Schaffer as director of veterinary professional services. Release

> RnRMarketResearch.com has released a report estimating that the global market for veterinary software is growing at a compound annual rate of 5.6% and is expected to reach $368.7 million by 2019. Release

> Cannabis Science acquired Equi-Pharm, a maker of specialty grooming and topical applications for horses and pets, for an undisclosed price. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…